Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
View / Open Files
Authors
Liu, Xinxue
Munro, Alasdair PS
Feng, Shuo
Janani, Leila
Aley, Parvinder K
Babbage, Gavin
Baxter, David
Bula, Marcin
Cathie, Katrina
Dejnirattisai, Wanwisa
Dodd, Kate
Enever, Yvanne
Qureshi, Ehsaan
Goodman, Anna L
Green, Christopher A
Harndahl, Linda
Haughney, John
Hicks, Alexander
van der Klaauw, Agatha A
Kwok, Jonathan
Libri, Vincenzo
Llewelyn, Martin J
McGregor, Alastair C
Minassian, Angela M
Moore, Patrick
Mughal, Mehmood
Mujadidi, Yama F
Holliday, Kyra
Osanlou, Orod
Osanlou, Rostam
Owens, Daniel R
Pacurar, Mihaela
Palfreeman, Adrian
Pan, Daniel
Rampling, Tommy
Regan, Karen
Saich, Stephen
Serafimova, Teona
Saralaya, Dinesh
Screaton, Gavin R
Sharma, Sunil
Sheridan, Ray
Sturdy, Ann
Supasa, Piyada
Thomson, Emma C
Todd, Shirley
Twelves, Chris
Read, Robert C
Charlton, Sue
Hallis, Bassam
Ramsay, Mary
Andrews, Nick
Lambe, Teresa
Nguyen-Van-Tam, Jonathan S
Cornelius, Victoria
Snape, Matthew D
Faust, Saul N
COV-BOOST study group
Publication Date
2022-06Journal Title
J Infect
ISSN
0163-4453
Publisher
Elsevier BV
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Liu, X., Munro, A. P., Feng, S., Janani, L., Aley, P. K., Babbage, G., Baxter, D., et al. (2022). Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.. J Infect https://doi.org/10.1016/j.jinf.2022.04.018
Abstract
OBJECTIVES: To evaluate the persistence of immunogenicity three months after third dose boosters. METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose. The analysis was conducted using all randomised participants who were SARS-CoV-2 naïve during the study. RESULTS: Amongst the 2883 participants randomised, there were 2422 SARS-CoV-2 naïve participants until D84 visit included in the analysis with median age of 70 (IQR: 30-94) years. In the participants who had two initial doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd), schedules using mRNA vaccines as third dose have the highest anti-spike IgG at D84 (e.g. geometric mean concentration of 8674 ELU/ml (95% CI: 7461-10,085) following ChAd/ChAd/BNT162b2 (Pfizer-BioNtech, hearafter referred to as BNT)). However, in people who had two initial doses of BNT there was no significant difference at D84 in people given ChAd versus BNT (geometric mean ratio (GMR) of 0.95 (95%CI: 0.78, 1.15). Also, people given Ad26.COV2.S (Janssen; hereafter referred to as Ad26) as a third dose had significantly higher anti-spike IgG at D84 than BNT (GMR of 1.20, 95%CI: 1.01,1.43). Responses at D84 between people who received BNT (15 μg) or BNT (30 μg) after ChAd/ChAd or BNT/BNT were similar, with anti-spike IgG GMRs of half-BNT (15 μg) versus BNT (30 μg) ranging between 0.74-0.86. The decay rate of cellular responses were similar between all the vaccine schedules and doses. CONCLUSIONS: 84 days after a third dose of COVID-19 vaccine the decay rates of humoral response were different between vaccines. Adenoviral vector vaccine anti-spike IgG concentrations at D84 following BNT/BNT initial doses were similar to or even higher than for a three dose (BNT/BNT/BNT) schedule. Half dose BNT immune responses were similar to full dose responses. While high antibody tires are desirable in situations of high transmission of new variants of concern, the maintenance of immune responses that confer long-lasting protection against severe disease or death is also of critical importance. Policymakers may also consider adenoviral vector, fractional dose of mRNA, or other non-mRNA vaccines as third doses.
Sponsorship
Wellcome Trust (210755/Z/18/Z)
Identifiers
35405168, PMC8993491
External DOI: https://doi.org/10.1016/j.jinf.2022.04.018
This record's URL: https://www.repository.cam.ac.uk/handle/1810/337153
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.